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We evaluated the effect of r-hirudin on an experimental model of disseminated 
intravascular coagulation (DIC) in rabbits, through the continuous infusion of 100 
~g/kg/hr of Escherichia coli endotoxin for a period of 6 hours, r-Hirudin (0.05, 0.3, 
and 0.6 mg/kg/hr) as treatment, or saline solution as placebo, were administered 
simultaneously with endotoxin. Severe DIC in the endotoxin control group was 
shown by impairment in hemostatic parameters, kidney fibrin deposition, and a 
high mortality rate. Medium and high doses of r-hirudin led to an improvement in 
such DIC-related parameters as platelet numbers and fibrinogen and protein C 
concentrations. High-dose r-hirudin also reduced consumption of antithrombin III 
(ATIII). All doses of r-hirudin prevented decreases in tissue plasminogen activator 
(t-PA) and reduced the increase in plasminogen activator inhibitor-I (PAl-I) activity 
observed at 2 hours after endotoxin administration. A significant reduction in kidney 
fibrin deposition was seen in medium- and high-dose r-hirudin groups. Additionally, 
the mortality rote in rabbits receiving medium- and high-dose r-hirudin was 10%, 
and that in rabbits receiving low-dose r-hirudin was 20%, as compared with a 
mortality rate of 70% in the control group. Protein C activity was significantly lower 
(p < 0.00 I) in nonsurviving rabbits. Moreover, there was a strong positive correlation 
(r = 0.68, p < 0.001) between protein C consumption and kidney fibrin deposition. 
We conclude that r-hirudin can be a useful drug in the clinical treatment of DIC. (J 
Lab Clin Med 1998;131:77-83) 
Abbreviations: ANOVA = analysis of variance; ATIII = antithrombin III; DIC = disseminated 
intravascular coagulation; K3-EDTA = tripotassium salt of ethylenediaminetetraacetic acid; 
LPS = lipopolysaccharide; MOF = multiple organ failure; PAl-1 = plasminogen activator 
inhibitor-I; t-PA = tissue plasminogen activator 
From the Laboratory of Vascular Biology and Thrombosis, He- 
matology Service, School of Medicine, University of Navarra. 
Supported by Grant PM 92-0167 from the Direcci6n General de 
Investigaci6n Cientffica y T6cnica of the Ministerio de Educacidn 
y Ciencia, Spain. 
Submitted for publication April 16, 1997; revision submitled July 
2, 1997; accepted Aug. 4, 1997. 
Reprint requests: E. Rocha, Hematology Service, University 
Clinic of Navarra, Avenida Pio XII, s/n, PO 4209, Paraplona, 
Spain. 
Copyright © 1998 by Mosby, Inc. 
0022-2143/98 $5.00 + 0 5/1/85676 
D IC is a serious and frequent complication of 
gram-negative bacterial sepsis. 1Despite the 
use of potent antibiotics and intensive sup- 
portive care, mortality among patients with sepsis- 
induced DIC remains close to 60%. 2 
Gram-negative bacteria include in their outer 
membrane a molecule called endotoxin or LPS. This 
substance leads monocytes and endothelial cells to 
generate several cytokines that in turn activate co- 
agulation, mainly through the extrinsic pathway. 3 As 
a result, large amounts of thrombin are generated. 
Thrombin transforms fibrinogen into fibrin and 
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Table I. Hemostatic parameters 2 and 6 hours after endotoxin infusion into rabbits in five different groups. 
Data shown as mean _ SEM percent of the basal value 
Platelets Fibrinogen AT III Protein C 
Group (%) (%) (%) (%) 
Saline control 2hr 96.29 + 12.61- 94.68 ± 10.2 93.04 _ 5.39 96,15 ± 2.88:1: 
6hr 96.29 + 6.545 94.35 + 9.395 89.39 _ 4.76* 96.73 _+ 3,505 
Endotoxin control 2hr 48.76 -+ 4.58 95.53 + 3,86 87.72 ± 3.93 58.65 + 5.20 
6hr 20.31 ± 3.53 58.22 ~ 5.06 73.07 +_ 5.80 15,15 +_ 3.30 
Hirudin (0.05 mg/kg/hr) 2hr 61.65 ± 5,65 89.75 ± 3,89 88.35 ± 2.15 67.80 _+ 5.08 
6hr 31.18 - 5.67 73.30 ± 5.72 80,13 _+ 4.89 17.84 _+ 4.43 
Hirudin (0.3 mg/kg/hr) 2hr 64.82 -+ 4.40 92.33 + 6.80 89.34 + 5.12 70.93 + 4.97 
6hr 46.02 -+ 4,611- 97.59 --_ 10.21- 79.25 _+ 5.13 39.35 _+ 4.961- 
Hirudin (0.6 mg/kg/hr) 2hr 71.17 ± 4.09* 93.84 ± 4.91 79.71 _+ 6.15 83.39 _+ 4.401- 
6hr 47.23 -+ 3.991- 83.94 + 5.69 108.3 _ 8.70* 46.22 ± 5.741- 
*p < 0.05 as compared with the endotoxin control group. 
tP < 0.01. 
:i:P < 0.001. 
stimulates platelet aggregation, with both effects 
leading to the formation of stable microthrombi. 
Exhaustion of ATIII and protein C--the main in- 
hibitors of coagulation--could perpetuate fibrin 
generation, 4'5 thus allowing the appearance of mi- 
crovascular thrombi in various organs, and subse- 
quent MOF. 6 
The fibrinolytic system, which lyses fibrin poly- 
mers, also seems to play an important role in the 
pathogenesis of DIC. Plasmin, the key enzyme in 
fibrinolysis, is generated through the activation of 
plasminogen by t-PA. The activity of t-PA is con- 
trolled by PAI-1. A marked increase in PAI-1 activ- 
ity subsequent to endotoxin infusion has been re- 
ported in healthy human subjects as well as in 
animal models and cultured endothelial cells.7 -9 
High activities of PAI-1 and low activities of t-PA 
have been found in patients with sepsis, m'u Re- 
duced fibrinolytic activity could contribute to the 
persistence of fibrin deposits in such cases. 
Consequently, a therapeutic approach that re- 
duces thrombin activity and improves fibrinolysis 
may be of interest, as suggested by preliminary stud- 
ies with experimentally induced DIC. 12-14 
Hirudin, a polypeptide initially isolated from the 
leech Hirudo medicinalis and currently available in 
recombinant form, is a selective thrombin inhibitor 
that exhibits several characteristics that make it an 
attractive agent for the management of DIC; for 
instance, it does not require cofactors uch as ATIII 
or heparin cofactor II for its activation, and it can 
effectively inhibit clot-bound thrombin in vitroJ 5'16 
Additionally, studies have pointed to a role of r- 
hirudin in improving endogenous fibrinolysis, al- 
though there is no agreement about this. 17-2° How- 
ever, human and animal studies have shown that 
r-hirudin may be useful in the treatment of venous 
and arterial thrombosis, 21and experimental models 
suggest that it may be an attractive agent for treating 
endotoxin-induced DIC. 22-26 
The goal of the present study was to evaluate the 
effect of different doses of r-hirudin on mortality 
and kidney fibrin deposition in a rabbit model of 
endotoxin-induced DIC. As a secondary endpoint, 
we analyzed the changes in several coagulation-re- 
lated and fibrinolytic parameters. 
METHODS 
Materials. recombinant desulfatohirudin variant 1 (Re- 
vasc), which exhibits a specific activity of 115,000 ATU/ 
mg, was obtained from Ciba-Geigy, Basel, Switzerland. 
Endotoxin (E. coli 0111:B4) was purchased from Difco 
Laboratories, Detroit, Mich. Urokinase was purchased 
from Roger Laboratories, Barcelona, Spain. 
Experimental model. Male New Zealand white rabbits 
(weight, 2 to 3 kg) were used in the study. Animals were 
anesthetized with an intramuscular injection of 30 mg/kg 
ketamine hydrochloride and 0.002 mg/kg xylacine hydro- 
chloride, followed by intramuscular supplements of ket- 
amine hydrochloride given throughout the experimet. 
DIC was induced by infusing endotoxin, in60 ml of saline 
solution, at a rate of 100 p.g/kg/hr (10 ml/hr) through the 
marginal ear vein of rabbits over a period of 6 hours. 
Treatments were begun simultaneously with endotoxin 
infusion, through the contralateral marginal ear vein. Five 
groups of animals were established, containing 10 animals 
each. Treatment groups (low-, medium-, and high-dose 
r-hirudin) were given 0.05, 0.3, and 0.6 mg/kg/hr r-hirudin 
in 60 ml of saline solution over a period of 6 hours (10 
ml/hr). The endotoxin control group was infused with 
saline solution as placebo (at a rate of 10 ml/hr) over a 
period of 6 hours. Ten further abbits, which were given 
neither endotoxin or r-himdin, were infused with saline 
solution through both marginal ear veins over a period of 
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Table I. Continued 
Plasminogen t-PA PAI-I 
(%) (%) (%) 
93.18 _+ 3,40 76,76 _+ 18.3 138.38 + 19.21- 
94,40 + 3,03:1: 105.7 _+ 15.4" 128.79 + 12.75 
88.68 -+ 3.88 70.04 +_ 4.48 564.01 + 11.1 
74.99 _+ 2.88 61.81 + 7.44 1178.3 _+ 31,2 
85.83 _+ 4.83 94.64 _+ 5.64* 388.60 _+ :-.0.41- 
81.30 -+ 3,52 108.7 -+ 7.871- 1147.5 _+ 78,4 
106.3 + 6.58 82.10 _+ 6.53 384.42 + 14.81- 
98.65 _+ 8.791- 85.86 + 8.55* 1284.3 _+ 69.9 
87.29 _+ 10.7 107.8 + 14,91- 326.77 _+ 61.51- 
87.15 _+ 9,64 146.1 _+ 19.15 933.96 _+ 165.1 
6 hours (10 ml/hr), and served as an additional control 
group. 
Surviving rabbits were killed at 24 hours after the start 
of each experiment, with an intravenous injection of 60 
mg/kg pentobarbital sodium (Nembutal). Kidneys were 
extracted from all animals (survivors and nonsurvivors) 
for subsequent histologic study. 
Sample collection and handling. Blood samples were 
collected via a catheter inserted into the femoral artery 
before the endotoxin infusion was begun, and again after 
2 and 6 hours. The blood samples were collected in 3.2% 
citrate at a ratio of 9 volumes of blood to 1 volume of 
citrate. Blood for measurement of t-PA activity was col- 
lected in Stabilyte tubes (Biopool, Umea, Sweden) to 
avoid interference by inhibitors of t-PA. Blood samples 
for measurement of fibrinogen, ATIII, protein C, plas- 
minogen, PAI-1, and t-PA activity were kept on ice for no 
more than 2 hours. Platelet-poor plasma was obtained by 
centrifugation at 1600 g for 20 minutes at 4 ° C, and was 
stored at -70°C until assayed. Tubes containing K3- 
EDTA were used to collect blood for platelet counts. 
Laboratory methods. Platelets were counted in an au- 
tomated STKS counter (Coulter, Inc., Hialeah, Fla.) Fi- 
brinogen was measured according to the method of 
Clauss. 27 ATIII, 28 protein C, 29 plasminogen, 3° t-PA activ- 
ity, 31 and PAI-1 activity 32 were measured with commer- 
cially available assays based on chromogenic substrates 
(Coamatic ATIII, Coamatic Protein C, Coamatic Plasmin- 
ogen, Coatest t-PA, and Coatest PAI; Chromogenix, 
Stockholm, Sweden). 
Histologic examination. Kidney sections were fixed in 
formalin, embedded in paraffin, stained with Masson 
trichrome, and examined for the presence of fibrin micro- 
thrombi by a pathologist unaware of the experimental 
design used in the study. Tissue sections were scored for 
fibrin microthrombi on a scale of 0 to 4, as previously 
described. 12 In brief, a score of 0 indicated the absence of 
fibrin, a score of 1 indicated partial fibrin deposition in 
some glomeruli, a score of 2 indicated partial deposition 
of fibrin in all glomeruli, a score of 3 signified large 
quantities of fibrin in all glomeruli, and a score of 4 
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signified the presence of fibrin thrombi in glomerular 
capillaries and in noncapillary vessels. 
Data analysis. Results at 2 and 6 hours were converted 
to percentages, with a value of 100% assumed for basal 
data, and were expressed as mean _+ SEM. Student's t test 
was used to seek differences between ~he endotoxin con- 
trol and saline solution control groups. One-way 
ANOVA, followed by Tukey's B test for multiple compar- 
isons, was used to compare the endotoxin and r-hirudin 
groups. The Kruskal-Wallis test, followed by the Mann- 
Whitney U test, was used to compare fibrin deposition in 
the endotoxin control and treatment groups. Differences 
in mortality rates at 24 hours were assessed with Fisher's 
exact est. Differences between surviving and nonsurviving 
animals in hemostatic parameters were assessed with Stu- 
dent's t test. Possible correlations between kidney fibrin 
deposition and hemostatic parameters were evaluated 
with Spearman's rank correlation test. 
RESULTS 
Table I shows the plasma levels, expressed in 
percentages with respect o the basal values, which 
were assumed to be 100%, of the different coagula- 
tion-related and fibrinolytic parameters analyzed 
throughout the study in the saline solution control, 
endotoxin control, and treated groups of animals. 
Effects of saline solution. No changes were found in 
hemostatic parameters during saline solution infu- 
sion (Table I). No rabbits died or showed evidence 
of kidney fibrin deposition with saline solution infu- 
sion. 
Effects of endotoxin infusion in rabbits given no treat- 
ment. Measurements made at 6 hours of infusion 
showed a significant decrease, with respect to the 
saline solution group, in platelet count, fibrinogen 
and protein C concentrations (p < 0.001), and 
ATI I I  (p < 0.05). Platelet numbers and the protein 
C concentration decreased significantly at 2 hours 
(p < 0.01) after the beginning of infusion. Levels of 
plasminogen and t-PA activity were significantly 
lower at 6 hours after the beginning of endotoxin 
infusion (p < 0.001 andp < 0.05, respectively) than 
at the corresponding time in the saline solution 
group. PAI-1 activity increased ramatically at 2 and 
6 hours after the beginning of endotoxin infusion 
(p < 0.001). 
Intense fibrin deposition was detected in most of 
the endotoxin-treated rabbits, even in noncapillary 
vessels. The average value for fibrin deposition ac- 
cording to the score described earlier was 2.61 + 
0.34, which was significantly higher (p < 0.01 than 
that in rabbits given only saline solution (score = 0). 
Seven of the 10 rabbits in the endotoxin group 
died within the first 24 hours after endotoxin infu- 
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Fig. 1. Score for fibrin deposition in kidneys (A) and mortality 
rate (B) in endotoxin control group and in rabbits receiving 
r-hirudin (low, medium, and high doses). Score values are ex- 
pressed as mean -+ SEM and mortality as percentage. *p < 0.05 
and **p < 0.01 as compared with the endotoxin control group. 
sion, whereas no animals died in the saline solution 
control group. 
Effects of r-hirudin on DIC. We found that infusion of 
medium and high doses of r-hirudin efficiently ame- 
liorated the platelet decrease at 6 hours after the 
beginning of endotoxin infusion by comparison with 
the endotoxin control group (p < 0.01), and also at 2 
hours by comparison with the high-dose endotoxin 
group (p < 0.05). A reduction in fibrinogen consump- 
tion was observed in the medium-dose group (p < 
0.01). As shown in Table I, high-dose r-hirudin pre- 
vented a decrease inATIII concentration (p < 0.05 at 
6 hours), whereas both medium (p < 0.01 at 6 hours) 
and high (p < 0.01 at 2 and 6 hours) doses of r-hirudin 
diminished the decrease in protein C concentration. 
Low doses of r-hirudin did not reduce the endotoxin- 
induced activation of coagulation. 
J Lab Clin Med 
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With regard to fibrinolytic parameters, all doses 
of r-hirudin reduce the increase in PAI-1 activity in 
blood samples taken at 2 hours after the beginning 
of endotoxin infusion (p < 0.01), although the ac- 
tivity values were still higher than the respective 
baseline values, and no effect was seen at 6 hours. 
An interesting finding was the significant prevention 
of the decrease in t-PA activity that was achieved 
with all three doses of r-hirudin at 6 hours after the 
beginning of endotoxin infusion, and at 2 hours with 
the low and high doses (Table I). In addition, the 
medium dose of r-hirudin corrected the mild de- 
crease in plasminogen observed at 6 hours in the 
endotoxin control group. 
The high and medium doses of r-hirudin signifi- 
cantly reduced fibrin deposition in the kidneys of 
test animals (scores: 1.05 __ 0.45, p < 0.05; and 
0.83 _+ 0.35, p < 0.01, respectively), whereas no 
significant effect was observed with the lowest dose 
(score: 3.05 + 0.44) (Fig. 1). 
Two of 10 rabbits (20%) died after treatment with 
low-dose hirudin, whereas only 1 of 10 (10%) died 
after treatment with the medium and high doses. 
The mortality rate in the latter two groups was 
significantly lower than in the endotoxin control 
group (p < 0.05) (Fig. 1). 
Hemostatic parameters in relation to mortality. When 
comparing the changes observed in the hemostatic 
parameters analyzed in surviving rabbits (n = 29) 
with those in animals that died in the endotoxin and 
treatment groups (n = 11), we found that plasma 
protein C activity was significantly lower at 2 and 6 
hours (p < 0.001) in animals that died within the 24 
hours after infusion (54.36% +- 4.42% and 12.98% 
+__ 3.58%) than in survivors (76.54% ___ 2.67% and 
36.43% ± 3.48%). A decrease in the platelet count 
at 2 hours (51.98% ± 6.34% vs 65.52% ___ 2.4%) and 
at 6 hours (26.06% + 5.94% vs 40.35% _+ 2.94%) 
was more evident in nonsurviving rabbits than in 
survivors (p < 0.05). Likewise, fibrinogen consump- 
tion at 6 hours (58.92% ___ 4.6% vs 85.63% ___ 4.62%) 
was significantly higher in nonsurviving rabbits (p < 
0.05). However, no differences in other parameters 
were assessed. On the other hand, nonsurviving rab- 
bits showed more intense kidney fibrin deposition 
than did surviving animals (2.75 ___ 0.36 vs 1.59 ± 
0.26). Although this last difference was not signifi- 
cant, it was at the limit of statistical significance (p = 
O.06). 
Remarkably, a strong positive correlation was 
found between protein C consumption and fibrin 
deposition at 2 and 6 hours (r = 0.42,p < 0.05, and 
r = 0.68, p < 0.001, respectively). There was also a 
positive correlation between kidney fibrin deposi- 
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tion and the decrease in platelet numbers and fibrin- 
ogen at 6 hours (r = 0.35 and r = 0.37, p < 0.05). 
DISCUSSION 
We studied the effects of several doses of r-him- 
din on an endotoxin-induced DIC model in rabbits. 
We found a significant decrease in platelet count; in 
fibrinogen, ATIII, protein C, and plasminogen con- 
centration and in t-PA activity; a dramatic increase 
in PAI-1 activity; intense kidney fibrin deposition; 
and a high mortality rate after endotoxin infusion. 
r-Hirudin decreased the consumption of platelets, 
fibrinogen, ATIII, and protein C, and atso de- 
creased fibrin deposition and the mortality rate in 
treated animals. These results are in accord with 
those in previous tudies howing that r-hirudin can 
decrease the consumption of platelets, fibrhaogen, 
and ATIII, as well as diminishing increases in fibrin 
monomers, thrombin-antithrombin complexes, fi- 
brinogen-fibrin degradation products, and fibrin 
deposition in different animal models of endotoxin- 
induced DIC. 22-24 Furthermore, a prior study with 
rabbits infused with gram-negative bacteria showed 
that mortality in animals treated with r-hirudin and 
antibiotic was lower than in animals treated with 
heparin and antibiotic. 25 
The improvement in protein C concentration with 
r-hirudin treatment was remarkable among the 
changes observed in coagulation parameters. The 
chief cause of protein C deficiency in endotoxin- 
induced DIC is not a decrease in production of this 
protein, but the huge generation of thrombin that 
occurs in the condition, as previously demonstrated 
in baboons. 33 The inhibition of thrombin by r-him- 
din decreases the formation of thrombin-thrombo- 
modulin complexes, thus avoiding activation of pro- 
tein C and its subsequent exhaustion. Moreover, a 
beneficial effect of treatment with r-hirudin in pre- 
venting protein C consumption can be assumed in 
endotoxin-induced DIC, since protein C levels in 
animals that died within 24 hours after endotoxin 
infusion in the present study were significantly lower 
than those in animals that did not die. These results 
are in accord with the recent finding that the sever- 
ity of protein C deficiency in human sepsis is greater 
in nonsurvivors than in survivors, and correlates 
with the extent of the skin lesion, which in turn 
reflects the severity of microvascular thrombosis in 
the condition. 34 Furthermore, in a model oF gram- 
negative sepsis in baboons, a monoclonal antibody 
able to block the activation of protein C increases 
mortality, which is reduced by protein C infusion. 35 
In the present study, we describe a strong correla- 
tion between the decrease in protein C concentra- 
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tion and the intensity of kidney fibrin deposition. 
Considering these findings collectively, it is tempting 
to speculate that protein C plays an etiologic role in 
the development of microthrombosis, although the 
possibility that this molecule is merely a sensitive 
and reliable marker of DIC cannot be excluded. 
Although endotoxin-induced inhibition of fibrino- 
lysis does not seem to be the critical factor in kidney 
fibrin deposition, it is obvious that an improvement 
in fibrinolysis could partly prevent fibrin deposi- 
t ionJ  2-14'36'37 In our endotoxin-induced DIC model, 
r-hirudin modified fibrinolysis. We found that it 
reduced PAI-1 activity at 2 hours and prevented the 
decrease in t-PA activity, enhancing its fibrinolytic 
potential. To our knowledge, no prior studies have 
been done of the effect of r-hirudin on fibrinolytic 
changes occurring during endotoxin-induced DIC. 
Although the infusion of r-hirudin into chimpanzees 
given endotoxin does not prevent impairment of 
fibrinolysis, it should be noted that the amount of 
endotoxin infused (4 ng/kg) failed to induce DICJ 7 
On the other hand, an improvement in fibrinolysis 
has been suggested after treatment with r-hirudin in 
a rabbit model of chronic venous thrombosis, i  and 
a recent study has shown that r-hirudin can enhance 
the extent of endogenous fibrinolysis in a model of 
jugular venous thrombosis, although PAI-1 and 
t-PA activity remained unchangedJ 9 In vitro exper- 
iments have shown that endothelial cell incubation 
with thrombin induces a significant increase in both 
PAI- antigen and activity levels, as well as in PAI-1 
mRNA.  38-4° Therefore, inhibition of thrombin could 
contribute to reduced production and secretion of 
PAI-1 by endothelial cells. On the other hand, pre- 
vention by r-hirudin of the decrease in t-PA activity 
induced by endotoxin could be due to the ability of 
r-hirudin to promote t-PA release from endothelial 
cells, as previously shown by our group. 2° Taken 
collectively, this information suggests that r-hirudin 
partly prevents hypofibrinolysis by reducing the in- 
crease in PAI-1 occurring in endotoxemia as well as 
by enhancing endothelial t-PA release. 
The lowest dose of r-hirudin used in the present 
study did not correct he impairment in coagulation 
induced by endotoxin, but did improve fibrinolysis 
by acting on both t-PA and PAI-1 activity, although 
these modifications were inadequate to produce a 
reduction in fibrin deposition. Also, although aclear 
tendency toward reduced mortality was observed 
with r-hirudin, the mortality rate was not signifi- 
cantly reduced, probably as a consequence of the 
number of animals used in the experiment. One 
explanation for the lack of utility of r-hirudin in 
improving coagulation and reducing kidney fibrin 
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deposition in this case may be that the dose used was 
from 2.5- to 5-fold lower than doses found to be 
effective in other experimental models of sepsis. 24'2s 
Although this dose (and even smaller doses) has 
been useful in human DIC, it is important o note 
that these cases of DIC were not the fulminant DIC 
induced by gram-negative bacteria. 41'42 On the other 
hand, it should be noted that the dose of hirudin 
effective in inhibiting thrombin depends on the spe- 
cies in which it is used, since the inhibitory rate 
constant of hirudin for thrombin varies among spe- 
cies. Another noteworthy observation about he low 
r-hirudin dose used in the present study was that 
despite its tendency to reduce the mortality rate 
among treated animals, it did not diminish kidney 
fibrin deposition. One possible xplanation could be 
that such a dose might have succeeded in preventing 
microthrombi in other organs, thus avoiding MOF, 
with a subsequent reduction in mortality. Kidneys 
are thought o be especially prone to fibrin forma- 
tion, with the result that higher doses of r-hirudin 
would be needed to arrest the development of mi- 
crothrombi, a concept coherent with the results ob- 
tained with the medium and high doses of r-hirudin 
in the present study. 
In a further step, we analyzed the possible corre- 
lations between hemostatic parameters and kidney 
fibrin deposition, mortality, or both, to investigate 
the pathophysiologic mechanisms operating in DIC 
and to identify prognostic markers in this condition. 
As expected, the decrease in platelet count and 
fibrinogen concentration was significantly greater in 
rabbits that died Within 24 hours after the beginning 
of the experiment than in those that survived, sug- 
gesting that these two parameters might have a cer- 
tain prognostic value in DIC. That both parameters 
also correlated with kidney fibrin deposition is not 
surprising, since both parameters play a critical role 
in the formation of microvascular thrombi. Some 
investigators have claimed that ATIII levels could 
have prognostic value in human DIC, and could also 
be useful in monitoring treatment, 43-45 but we did 
not find differences in ATIII behavior in surviving 
and nonsurviving animals. However, nonsurviving 
rabbits showed a significantly greater decrease in 
protein C concentration, which correlated with kid- 
ney fibrin deposition. These findings suggest hat 
protein C may not only be a reliable prognostic 
marker in DIC, but may also play a role in the 
pathogenesis of microthrombosis, as has recently 
been suggested. 34 
We conclude that treatment with r-hirudin can 
decrease, in a dose-dependent manner, both kidney 
fibrin deposition and the mortality rate in a model of 
endotoxin-induced DIC in rabbits. In the light of our 
data, this direct inhibitor of thrombin may have a 
twofold benefit in improving the function of antico- 
agulant systems, particularly by preventing exhaus- 
tion of protein C, and enhancing fibrinolytic poten- 
tial. If these findings apply to humans, our results 
would suggest that administration of r-hirudin may 
improve the survival of patients with endotoxin- 
induced DIC. However, because r-hirudin in our 
study was given at the same time as exposure to 
endotoxin, we cannot confirm that it is efficacious 
once DIC has begun, and further studies are needed 
to assess this issue. 
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